The obesity paradox in super-elderly patients with heart failure: a retrospective cohort study
Heart and Vessels · 2026-02 · 41 (2) · 115-124
DOI: 10.1007/s00380-025-02597-5 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Heart and Vessels, online erschienen am 17.09.2025. Verfasst von Takahiro Tachibana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. Hauptthemen laut MEDLINE: Heart Failure, Obesity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Obesity is an independent risk factor for heart failure (HF) onset; however, weight loss is an independent poor prognostic factor in patients with HF. According to the obesity paradox, higher body weight is associated with better prognosis in these patients. This retrospective cohort study investigated the obesity paradox in super-elderly, understudied patients (aged ≥ 85 years) with HF and examined its impact on all-cause mortality. We included patients hospitalized for HF between April 2015 and March 2023. Participants were divided into four age groups: Groups A (< 65 years), B (65-74 years), C (75-84 years, elderly), and D (≥ 85 years, super-elderly). The primary endpoint was the 1-year all-cause mortality rate after discharge. The secondary endpoints included cardiac and non-cardiac death rates and all-cause mortality rates stratified by left ventricular ejection fraction (LVEF). Overall, 3,811 individuals (mean age: 74.3 years, 60.4% men) were included. A trend toward higher all-cause mortality rates associated with underweight (body mass index [BMI] < 18.5 kg/m2) was observed in all age groups. Patients with obesity (BMI ≥ 25.0 kg/m2) had significantly better survival than other patients. Underweight was associated with a higher cardiac death rate compared with the other weight categories (P = 0.014, 0.039, and 0.022 for groups B, C, and D, respectively). In the analysis stratified by LVEF, underweight was significantly associated with a higher cardiac death rate in patients with HF with preserved LVEF compared with the other weight categories (P < 0.001). The obesity paradox in the super-elderly population was confirmed. It is important to consider BMI in HF management and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
- Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. ykubota@nms.ac.jp.
- Department of Health Care Administration, Nippon Medical School, Tokyo, Japan.
- Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
- Department of Pharmaceutical Service, Nippon Medical School Hospital, Tokyo, Japan.
- Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, Tokyo, Japan.
Zitieren
APA
Tachibana, T., Kubota, Y., Nishino, T., Kato, K., Iwade, Y., Hayashi, D., Watanabe, Y., Miyachi, H., Tara, S., & Asai, K. (2026). The obesity paradox in super-elderly patients with heart failure: a retrospective cohort study. Heart and Vessels, 41(2), 115-124. https://doi.org/10.1007/s00380-025-02597-5
Vancouver
Tachibana T, Kubota Y, Nishino T, Kato K, Iwade Y, Hayashi D, et al. The obesity paradox in super-elderly patients with heart failure: a retrospective cohort study. Heart and Vessels. 2026;41(2):115-124. doi:10.1007/s00380-025-02597-5
BibTeX
@article{Tachibana2026,
author = {Tachibana, Takahiro and Kubota, Yoshiaki and Nishino, Takuya and Kato, Katsuhito and Iwade, Yoshiki and Hayashi, Daisuke and Watanabe, Yukihiro and Miyachi, Hideki and Tara, Shuhei and Asai, Kuniya},
title = {The obesity paradox in super-elderly patients with heart failure: a retrospective cohort study},
journal = {Heart and Vessels},
year = {2026},
volume = {41},
number = {2},
pages = {115--124},
doi = {10.1007/s00380-025-02597-5}
}
EUVIMED